Migraine is a common and debilitating brain disorder that remains poorly treated for many patients. There are approximately 650 million headaches treated each year* and approximately 1.2 million emergency room visits due to migraines.
Approximately 33.8 million people suffer from either episodic or chronic migraine. Of those, an estimated 20% to 30% either do not respond to or cannot tolerate the market-leading triptan drug class.
The total migraine drug market is approximately $3.45 billion and is projected to continue growing at a rate of 12% per year through 2027.1
Trevena is developing TRV250 for the acute treatment of migraine. Unlike currently approved migraine therapies, it targets the delta-opioid receptor (delta receptor). Using a novel mechanism of action, TRV250 preferentially engages the signaling pathway responsible for efficacy, with reduced activation of the signaling pathway associated with delta receptor-mediated adverse effects.
The delta receptor is located throughout the brain and plays a role in regulating pain, mood, and anxiety.2 However, the therapeutic potential of this receptor in CNS-mediated diseases has remained largely untapped, due to debilitating adverse effects associated with this receptor target.3 The discovery innovations made by Trevena have yielded TRV250, a compound that, in non-clinical and early clinical studies, appears to reduce the risk of such adverse effects, thus opening the possibility of investigating the therapeutic benefits of a delta receptor agonist in humans.4
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA||Approved|
|TRV250||Delta receptor||Acute migraine||PH1||Oral/Subcutaneous PC complete||PH1 in progress||PH2 not started||PH3 not started||NDA not started||Approved not started|
*Chronic migraine defined as >15 attacks per month.